The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
本公开涉及能够穿透血脑屏障以调节
EGFR
酪氨酸激酶活性的化合物。本公开进一步涉及治疗胶质母细胞瘤和其他
EGFR介导的癌症的方法。本公开进一步涉及治疗已确定在
抑制剂存在下具有改变
葡萄糖代谢的胶质母细胞瘤和其他
EGFR介导的癌症的方法。本公开还提供了向受试者给予
葡萄糖代谢
抑制剂和细胞质p53稳定剂的方法。